Zacks Investment Research upgraded shares of Alpine Immune Sciences (NASDAQ:ALPN) from a hold rating to a buy rating in a research note published on Thursday, January 4th. The brokerage currently has $13.00 target price on the biotechnology company’s stock.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

Separately, ValuEngine upgraded shares of Alpine Immune Sciences from a strong sell rating to a sell rating in a report on Thursday, November 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $10.50.

Shares of Alpine Immune Sciences (ALPN) opened at $11.58 on Thursday. Alpine Immune Sciences has a 12 month low of $7.20 and a 12 month high of $14.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 32.38 and a quick ratio of 32.38.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Monday, November 13th. The biotechnology company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.43. The business had revenue of $0.13 million during the quarter. equities analysts expect that Alpine Immune Sciences will post -1.16 EPS for the current year.

A hedge fund recently bought a new stake in Alpine Immune Sciences stock. Sowell Financial Services LLC acquired a new position in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned 0.40% of Alpine Immune Sciences at the end of the most recent reporting period. Institutional investors and hedge funds own 56.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Alpine Immune Sciences (NASDAQ:ALPN) Upgraded to “Buy” at Zacks Investment Research” was originally published by Marea Informative and is owned by of Marea Informative. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.mareainformativa.com/alpine-immune-sciences-alpn-lifted-to-buy-at-zacks-investment-research-updated-updated-updated/125989/.

About Alpine Immune Sciences

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.